RecruitingPHASE1, PHASE2NCT06016920
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nykode Therapeutics ASA
- Principal Investigator
- Åse Bratland, MD, PhDOslo University Hospital
- Intervention
- VB10.16(biological)
- Enrollment
- 51 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (17)
- Fakultni nemocnice Olomouc, Olomuoc, Olomouc, Czechia
- Hôpital de la Pitié - Salpétrière in Paris, Paris, Paris, France
- Hospices Civils De Lyon, Lyon, France
- CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM), Montpellier, France
- Institut Gustave Roussy, Paris, Paris, France
- Universität Leipzig Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Leipzig, Germany
- Orszagos Onkologiai Intezet, Budapest, Budapest, Hungary
- University of Bergen, Haukeland University Hospital, Bergen, Norway
- Oslo Universitetssykehus, Oslo, Norway
- Uniwersyteckie Cetrum Kliniczne, Gdansk, Poland
- Narodowy Instytut Onkologii-im Marii Sklodowskiej-Curie Panstwowy Instytut, Gliwice, Poland
- KO-MED Centra Kliniczne Lublin II, Lublin, Lublin, Poland
- Hospital del Mar, Barcelona, Barcelona, Spain
- Institut Catala d'Oncologia, Barcelona, Barcelona, Spain
- Hospital Universitario Virgen de las Nieves, Granada, Granada, Spain
- +2 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06016920 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →